Browse RNF31

Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF16678 UB-associated-like domain of HOIP or E3 ubiquitin-protein ligase
PF01485 IBR domain
PF09409 PUB domain
Function

E3 ubiquitin-protein ligase component of the LUBAC complex which conjugates linear ('Met-1'-linked) polyubiquitin chains to substrates and plays a key role in NF-kappa-B activation and regulation of inflammation (PubMed:17006537, PubMed:19136968, PubMed:20005846, PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:22863777). LUBAC conjugates linear polyubiquitin to IKBKG and RIPK1 and is involved in activation of the canonical NF-kappa-B and the JNK signaling pathways (PubMed:17006537, PubMed:19136968, PubMed:20005846, PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:22863777). Linear ubiquitination mediated by the LUBAC complex interferes with TNF-induced cell death and thereby prevents inflammation (PubMed:21455173). LUBAC is proposed to be recruited to the TNF-R1 signaling complex (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and possibly other components contributing to the stability of the complex (PubMed:20005846). Together with otulin, the LUBAC complex regulates the canonical Wnt signaling during angiogenesis. Binds polyubiquitin of different linkage types (PubMed:23708998).

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006626 protein targeting to mitochondrion
GO:0006839 mitochondrial transport
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0023035 CD40 signaling pathway
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051222 positive regulation of protein transport
GO:0060759 regulation of response to cytokine stimulus
GO:0070585 protein localization to mitochondrion
GO:0071356 cellular response to tumor necrosis factor
GO:0072655 establishment of protein localization to mitochondrion
GO:0090316 positive regulation of intracellular protein transport
GO:0097039 protein linear polyubiquitination
GO:1903214 regulation of protein targeting to mitochondrion
GO:1903533 regulation of protein targeting
GO:1903747 regulation of establishment of protein localization to mitochondrion
GO:1903749 positive regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1903955 positive regulation of protein targeting to mitochondrion
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0032182 ubiquitin-like protein binding
GO:0043130 ubiquitin binding
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0009898 cytoplasmic side of plasma membrane
GO:0035631 CD40 receptor complex
GO:0043235 receptor complex
GO:0071797 LUBAC complex
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
Reactome R-HSA-73887: Death Receptor Signalling
R-HSA-5357905: Regulation of TNFR1 signaling
R-HSA-162582: Signal Transduction
R-HSA-75893: TNF signaling
R-HSA-5357956: TNFR1-induced NFkappaB signaling pathway
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF31 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF31 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.77; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -3.40; FDR: 0.00545 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 5.20; FDR: 0.002 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2020.362
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4770.797
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0010.999
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4720.131
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3520.876
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6270.831
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.230.517
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2910.842
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1450.93
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0310.985
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2530.916
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0370.526
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF31. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF31. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF31.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF31. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF31 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF31 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF31
Namering finger protein 31
Aliases ZIBRA; FLJ10111; FLJ23501; HOIP; HOIL-1-interacting protein; zinc in-between-RING-finger ubiquitin-associate ......
Chromosomal Location14q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF31 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.